J 2008

The EUROclass trial: defining subgroups in common variable immunodeficiency.

WEHR, Claudia, Teemu KIVIOJA, Christian SCHMITT, Berne FERRY, Torsten WITTE et. al.

Basic information

Original name

The EUROclass trial: defining subgroups in common variable immunodeficiency.

Name in Czech

EUROclasss: definice podskupin pacientů s běžným variabilním imunodeficitem

Authors

WEHR, Claudia, Teemu KIVIOJA, Christian SCHMITT, Berne FERRY, Torsten WITTE, Efrem EREN, Marcela VLKOVA, Manuel HERNANDEZ, Drahomíra DEDKOVA, Philip R. BOS, Gonke POERKSEN, Horst VON BEMUTH, Ulrich BAUMANN, Sigune GOLDACKER, Sylvia GUTENBERGER, Michael SCHLESIER, Florence BERGERON-VAN DER CRUYSSEN, Magali LE GARFF, Patrice DEBRÉ, Roland JACOBS, John JONES, Elizabeth BATERMAN, Jiří LITZMAN, P. Martin VAN HAGEN, Alessandro PLEBANI, Reinhold E. SCHMIDT, Vojtěch THON, Isabella QUINTI, Teresa ESPANOL, A. David WEBSTER, Helen CHAPEL, Mauno VIHINEN, Eric OKSENHENDLER, Hans Hartmut PETER and Klaus WARNATZ

Edition

Blood, 2008, 0006-4971

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30102 Immunology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 10.432

Organization unit

Faculty of Medicine

UT WoS

000252002000016

Keywords (in Czech)

běžná variabilní imunodeficience; FACS; klasifikace

Keywords in English

common variable immunodefciency; B-lymphocytes; classification

Tags

International impact, Reviewed
Změněno: 2/4/2010 08:02, prof. MUDr. Jiří Litzman, CSc.

Abstract

V originále

The heterogeneity of common variable immunodeficiency (CVID) calls for a classification addressing pathogenic mechanisms as well as clinical relevance. This European multicenter trial was initiated to develop a consensus of 2 existing classification schemes based on flowcytometric B-cell phenotyping and the clinical course. The clinical evaluation of 303 patients with the established diagnosis of CVID demonstrated a significant coincidence of granulomatous disease, autoimmune cytopenia, and splenomegaly. Phenotyping of B-cell subpopulations confirmed a severe reduction of switched memory B cells in most of the patients that was associated with a higher risk for splenomegaly and granulomatous disease. An expansion of CD21(low) B cells marked patients with splenomegaly. Lymphadenopathy was significantly linked with transitional B-cell expansion. Based on these findings and pathogenic consideration of B-cell differentiation, we suggest an improved classification for CVID (EUROclass), separating patients with nearly absent B cells (less than 1%), severely reduced switched memory B cells (less than 2%), and expansion of transitional (more than 9%) or CD21(low) B cells (more than 10%). Whereas the first group contains all patients with severe defects of early B-cell differentiation, severely reduced switched memory B cells indicate a defective germinal center development as found in inducible constimulator (ICOS) or CD40L deficiency. The underlying defects of expanded transitional or CD21(low) B cells remain to be elucidated.

In Czech

Byla získána data od 303 pacientů s běžným variabilním imunodeficitem ( CVID). Na základě počtu buněk definovaných B-lymfocytárních subpopulací u jednotlivých pacientů bylo navrženo nové klasifikační schéma CVID.

Links

NR9035, research and development project
Name: Specifická protilátková odpověď u pacientů s poruchami imunity